EMA Conflict Of Interest Guidelines Sets Up Five-Year Exclusion Window For Committee Chairs
Executive SummaryThe European Medicines Agency has reviewed its conflict of interest policy for members of its Scientific Committees with a view to ensuring that they are not unduly influenced by the pharmaceutical industry.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.